Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
30 October 2023 - 11:00PM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunological diseases, will report third quarter 2023
financial results before the Nasdaq Global Market open on Monday,
November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer,
will host a conference call and webcast at 8:30am ET to provide an
update on corporate developments and to discuss third quarter
financial results.
Webcast Information:
Interested parties may join the webcast via the Investors
section of the Astria website, www.astriatx.com, or with the
following link: https://lifescievents.com/event/astria-2/.
Please connect to the webcast several minutes prior to the start
of the broadcast to ensure adequate time for any software download
that may be required. The webcast will be archived for 90 days.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our
mission is to bring life-changing therapies to patients and
families affected by allergic and immunological diseases. Our lead
program, STAR-0215, is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx
and on Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231030913007/en/
Investor Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From Apr 2024 to May 2024
Astria Therapeutics (NASDAQ:ATXS)
Historical Stock Chart
From May 2023 to May 2024